THC Biomed Intl Statistics
Total Valuation
THC Biomed Intl has a market cap or net worth of 2.44 million. The enterprise value is 5.86 million.
| Market Cap | 2.44M |
| Enterprise Value | 5.86M |
Important Dates
The next estimated earnings date is Friday, June 27, 2025.
| Earnings Date | Jun 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.48 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.16 |
| EV / Sales | 3.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -22.20 |
Financial Position
The company has a current ratio of 0.41, with a Debt / Equity ratio of 1.02.
| Current Ratio | 0.41 |
| Quick Ratio | 0.04 |
| Debt / Equity | 1.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -13.43 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.47% and return on invested capital (ROIC) is -20.19%.
| Return on Equity (ROE) | -56.47% |
| Return on Assets (ROA) | -15.27% |
| Return on Invested Capital (ROIC) | -20.19% |
| Return on Capital Employed (ROCE) | -63.86% |
| Revenue Per Employee | 46,939 |
| Profits Per Employee | -77,352 |
| Employee Count | 35 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 1.16 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.71% in the last 52 weeks. The beta is 0.09, so THC Biomed Intl's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -93.71% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 37.30 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, THC Biomed Intl had revenue of 1.64 million and -2.71 million in losses. Loss per share was -0.02.
| Revenue | 1.64M |
| Gross Profit | -856,621 |
| Operating Income | -2.67M |
| Pretax Income | -2.71M |
| Net Income | -2.71M |
| EBITDA | -2.21M |
| EBIT | -2.67M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 151,179 in cash and 3.54 million in debt, giving a net cash position of -3.39 million.
| Cash & Cash Equivalents | 151,179 |
| Total Debt | 3.54M |
| Net Cash | -3.39M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 3.47M |
| Book Value Per Share | 0.02 |
| Working Capital | -3.49M |
Cash Flow
In the last 12 months, operating cash flow was -280,406 and capital expenditures 16,561, giving a free cash flow of -263,845.
| Operating Cash Flow | -280,406 |
| Capital Expenditures | 16,561 |
| Free Cash Flow | -263,845 |
| FCF Per Share | n/a |
Margins
Gross margin is -52.14%, with operating and profit margins of -162.67% and -164.79%.
| Gross Margin | -52.14% |
| Operating Margin | -162.67% |
| Pretax Margin | -164.79% |
| Profit Margin | -164.79% |
| EBITDA Margin | -134.30% |
| EBIT Margin | -162.67% |
| FCF Margin | n/a |
Dividends & Yields
THC Biomed Intl does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.75% |
| Shareholder Yield | 0.75% |
| Earnings Yield | -111.07% |
| FCF Yield | -10.82% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
THC Biomed Intl has an Altman Z-Score of -3.41. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.41 |
| Piotroski F-Score | n/a |